But the list price is $419 000.
https://www.fiercepharma.com/marketing/bristol-myers-bluebir...
But the list price is $419 000.
https://www.fiercepharma.com/marketing/bristol-myers-bluebir...
Consider a disease has an effective daily pill treatment where each pill costs $.50 to make. Someone comes along with a single pill that costs $1000 to make but cures you. The cure developers have just spent a lot of money on R&D and need to make a profit on the administration of the cure, so they need to price it significantly over their production costs. The established treatment on the other hand has a war chest and can recoup short term losses in the long run, so they can afford to drop their prices or even give it away for free for a limited time. Perhaps some segment of the population will pay a hefty premium just for not having to deal with the hassle of treatment, but most people don't have thousands to spend on such a luxury and will stick with the option they can afford right now, even though it will wind up costing more over the course of their lifetime.
They can't keep your arm in a cast because fixing it with an operation is top expansive.
The fact is that $1000 is not the cost of producing the pill, that is the amount they can charge for the pill while still getting people to pay for it. When there is no competition, and people would die without it, prices get very high very quickly. There is an extremely large barrier to entry for new medicines, and pharmaceutical companies are structured to recoup the massive development costs by charging large sums for inexpensive to produce goods that they have essentially a monopoly over. If it costs billions of dollars to develop a cure, that cure is going to have to be expensive, but a cure administered repeatedly can amortize those costs over many low-cost doses, while a one-time cure can't. Insurance companies are all about spreading costs over time - paying out large sums to large numbers of people all at once is a lot more problematic than smaller, predictable payouts over a longer period of time. It is in their best interest as well for you to manage the disease.
It would be good to see some actual economists weigh in on this.
Cancer meds are really expensive, a four month cycle in myeloma ( where most of the time 2/3/4 drugs are combined) can cost more than 250k. Revlimid, a maintainance drug often given for years can cost 20k a month (in India it's $150 a month).